🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 101 of 116

  1. Nivolumab

    United Therapeutics Europe Ltd

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  2. Nivolumab

    Nektar Therapeutics UK Limited

    Renal Cell Carcinoma

    phase 1 mab completed

    1 trial

  3. Nivolumab

    Iovance Biotherapeutics B.V.

    Melanoma (Skin)

    phase 1 small molecule completed

    1 trial

  4. Nivolumab

    Iovance Biotherapeutics B.V.

    Non-Small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  5. Nivolumab

    Jazz Pharmaceuticals Ireland Limited

    Small-cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  6. ODSH

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 1 small molecule completed

    1 trial

  7. OKI-179

    OnKure Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  8. OKI-219

    OnKure Therapeutics

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  9. OMP-131R10

    Mereo BioPharma Group plc

    Advanced Relapsed Tumors

    phase 1 small molecule completed

    1 trial

  10. OMP-18R5

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 mab completed

    1 trial

  11. OMP-21M18

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  12. OMP-21M18

    Mereo BioPharma Group plc

    Colorectal Cancer

    phase 1 small molecule completed

    1 trial

  13. OMP-305B83

    Mereo BioPharma Group plc

    Cancer Ovaries

    phase 1 small molecule completed

    1 trial

  14. OMP-305B83

    Mereo BioPharma Group plc

    Metastatic Colorectal Cancer

    phase 1 small molecule terminated

    1 trial

  15. OMP-305B83

    Mereo BioPharma Group plc

    Advanced Solid Tumor Malignancies

    phase 1 small molecule completed

    1 trial

  16. OMP-313M32

    Mereo BioPharma Group plc

    Locally Advanced Cancer

    phase 1 small molecule terminated

    1 trial

  17. OMP-336B11

    Mereo BioPharma Group plc

    Locally Advanced Malignant Neoplasm

    phase 1 small molecule terminated

    1 trial

  18. OMP-52M51

    Mereo BioPharma Group plc

    Relapsed or Refractory Solid Tumors

    phase 1 small molecule completed

    1 trial

  19. OMP-54F28

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 mab completed

    1 trial

  20. OMP-54F28 with Sorafenib

    Mereo BioPharma Group plc

    Hepatocellular Cancer

    phase 1 small molecule completed

    1 trial

  21. OMP-54F28, Nab-Paclitaxel and Gemcitabine

    Mereo BioPharma Group plc

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  22. OMP-54F28, Paclitaxel and Carboplatin

    Mereo BioPharma Group plc

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

  23. OMP-59R5

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  24. OMTX705-006 Phase 1b

    Lacuna Pharma Pty Ltd

    Advanced/Metastatic Pancreatic Adenocarcinoma

    phase 1 other active

    1 trial

  25. ONC206

    Jazz Pharmaceuticals Ireland Limited

    Central Nervous System Neoplasms

    phase 1 small molecule active

    1 trial

  26. ONC206 Powder

    AXIM BIOTECHNOLOGIES, INC.

    Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors

    phase 1 small molecule active

    1 trial

  27. ONO-4578

    Ono Pharmaceutical Co.,

    Metastatic Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  28. OP-3136

    Olema Pharmaceuticals

    Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)

    phase 1 small molecule active

    1 trial

  29. OPB-31121

    Otsuka Beijing Research Institute

    Non-Hodgkin's Lymphoma(NHL)

    phase 1 small molecule completed

    1 trial

  30. OPB-51602

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma

    phase 1 small molecule terminated

    1 trial

  31. ORIC-101

    Topiloric/Uriadec

    Prostatic Neoplasms

    phase 1 small molecule terminated

    1 trial

  32. ORIC-101

    Topiloric/Uriadec

    Solid Tumor

    phase 1 small molecule terminated

    1 trial

  33. ORIC-114 Dose 1 + amivantamab

    Topiloric/Uriadec

    Solid Tumors

    phase 1 small molecule active

    1 trial

  34. ORIC-944

    Topiloric/Uriadec

    Metastatic Prostate Cancer

    phase 1 small molecule active

    1 trial

  35. Odronextamab

    Regeneron UK Limited

    B-cell Non-Hodgkins Lymphoma (B-NHL)

    phase 1 small molecule active

    1 trial

  36. Odronextamab multiple dose levels

    Regeneron UK Limited

    Non-Hodgkin Lymphoma

    phase 1 small molecule completed

    1 trial

  37. Olaparib tablets, 150 mg

    Sandoz Pty Ltd

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

  38. Olutasidenib Investigational Agent Administration

    RIGEL PHARMACEUTICALS INC

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  39. Olverembatinib, APG-2575, Dexamethasone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphoblastic Leukemia, Acute, Childhood

    phase 1 small molecule active

    1 trial

  40. Omacetaxine

    Teva Pharma GmbH

    Hematologic Tumors

    phase 1 small molecule completed

    1 trial

  41. Onartuzumab

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 1 small molecule completed

    1 trial

  42. Oncolytic Virus SDJ001

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Tumor

    phase 1 small molecule active

    1 trial

  43. Open-label, non-randomised, single-dose, one sequence, two-period, cross-over study to investigate the effect of inhibition of P-glycoprotein and breast cancer resistance protein transporters by cyclosporine on the pharmacokinetics of CHF6001 in healthy volunteers.

    Chiesi Farmaceutici S.p.A

    Chronic obstructive pulmonary disease

    phase 1 other active

    1 trial

  44. Optical PD-L1 imaging using Quantitative Fluorescence Endoscopy in locally advanced esophageal cancer using durvalumab-680LT: a phase I multicenter feasibility and safety study

    Disc Medicine

    Esophageal cancer

    phase 1 other active

    1 trial

  45. Osimertinib

    PUMA BIOTECHNOLOGY, INC.

    Lung Cancer Metastatic

    phase 1 small molecule active

    1 trial

  46. PAN-301-1

    Sensei Biotherapeutics

    Prostate Cancer

    phase 1 mab completed

    1 trial

  47. PARP inhibitor BMN-673

    BioMarin Pharmaceutical Australia Pty Ltd

    Metastatic Cancer

    phase 1 small molecule completed

    1 trial

  48. PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib

    Chongqing Precision Biotech Co., Ltd

    Non-small Cell Lung Cancer

    phase 1 mab completed

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.